阅读说明：本技术 用于治疗癌症的方法和组合物 (Methods and compositions for treating cancer ) 是由 F·格里瑟利 A·蒂汉 A·本纳瑟尔·格里瑟利 于 2019-08-06 设计创作，主要内容包括：本发明涉及用于治疗癌症的方法。许多癌症具有干性标记以去分化为未成熟的祖细胞,从而赋予肿瘤克隆从胎儿发育中重新表达基因的能力。发明人获得了每组五只小鼠,其分别接受7天和14天的2x106个辐射的hESC细胞的两次加强疫苗接种,这些细胞与3种不同的佐剂混合：500μgTLR3、50μg TLR9激动剂或50μg/mlQuil-疫苗佐剂。14天后,将5x1044T1个细胞注入小鼠的乳腺脂肪垫中,并以4mg/ml的剂量将丙戊酸添加到饮用水中。他们已经表明,与未接种疫苗的小鼠相反,与使用TLR9激动剂或Quil-疫苗佐剂相比,用hESC和TLR3激动剂联合接种的小鼠产生了最大的乳腺肿瘤体积减少(p<0.001)。因此,本发明涉及用i)诱导抗原的MHC-I呈递的试剂,ii)含有免疫原性成分的疫苗组合物和iii)佐剂治疗患有癌症的受试者的方法。(The present invention relates to methods for treating cancer. Many cancers have sternness markers to dedifferentiate into immature progenitor cells, thereby conferring tumor clones the ability to re-express genes from fetal development. The inventors obtained five mice per group that received two booster vaccinations of 2x106 irradiated hESC cells for 7 and 14 days, respectively, mixed with 3 different adjuvants: 500 μ g TLR3, 50 μ g TLR9 agonist or 50 μ g/ml Quil- A vaccine adjuvant. After 14 days, 5x1044T1 cells were injected into the mammary fat pad of mice and valproic acid was added to the drinking water at a dose of 4 mg/ml. They have shown that in contrast to unvaccinated mice, either the TLR9 agonist or Quil-)